Genomic aberrations and survival in chronic lymphocytic leukemia - PubMed (original) (raw)
. 2000 Dec 28;343(26):1910-6.
doi: 10.1056/NEJM200012283432602.
Affiliations
- PMID: 11136261
- DOI: 10.1056/NEJM200012283432602
Free article
Genomic aberrations and survival in chronic lymphocytic leukemia
H Döhner et al. N Engl J Med. 2000.
Free article
Abstract
Background: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications.
Methods: Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22-23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings.
Results: Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (7 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information.
Conclusions: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies.
Comment in
- Chromosomal abnormalities in chronic lymphocytic leukemia.
Garcia-Manero G. Garcia-Manero G. N Engl J Med. 2001 Apr 19;344(16):1254. doi: 10.1056/NEJM200104193441615. N Engl J Med. 2001. PMID: 11314693 No abstract available.
Similar articles
- Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia.
Durak B, Akay OM, Aslan V, Ozdemir M, Sahin F, Artan S, Gülbas Z. Durak B, et al. Cancer Genet Cytogenet. 2009 Jan 15;188(2):65-9. doi: 10.1016/j.cancergencyto.2008.08.019. Cancer Genet Cytogenet. 2009. PMID: 19100507 - Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A. Quijano S, et al. Cytometry B Clin Cytom. 2008 May;74(3):139-49. doi: 10.1002/cyto.b.20390. Cytometry B Clin Cytom. 2008. PMID: 18061951 - Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Cavazzini F, Milani R, Minotto C, Tieghi A, Della Porta M, Agostini P, Tammiso E, Negrini M, Castoldi G. Cuneo A, et al. Haematologica. 2002 Jan;87(1):44-51. Haematologica. 2002. PMID: 11801464 - Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Stilgenbauer S, et al. Leukemia. 2002 Jun;16(6):993-1007. doi: 10.1038/sj.leu.2402537. Leukemia. 2002. PMID: 12040431 Review.
Cited by
- Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia.
Mátrai Z, Andrikovics H, Szilvási A, Bors A, Kozma A, Ádám E, Halm G, Karászi É, Tordai A, Masszi T. Mátrai Z, et al. Pathol Oncol Res. 2017 Jan;23(1):165-171. doi: 10.1007/s12253-016-0132-z. Epub 2016 Oct 18. Pathol Oncol Res. 2017. PMID: 27757836 - GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
Macias-Perez IM, Flinn IW. Macias-Perez IM, et al. Curr Hematol Malig Rep. 2013 Mar;8(1):22-7. doi: 10.1007/s11899-012-0142-1. Curr Hematol Malig Rep. 2013. PMID: 23114654 Review. - Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M. Prinz C, et al. Mol Cancer. 2015 Jun 4;14:114. doi: 10.1186/s12943-015-0378-1. Mol Cancer. 2015. PMID: 26041471 Free PMC article. - TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.
Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, Bandovic J, Stankovic T, Barrientos J, Kolitz JE, Allen SL, Rai K, Chu CC, Chiorazzi N. Mongini PK, et al. J Immunol. 2015 Aug 1;195(3):901-23. doi: 10.4049/jimmunol.1403189. Epub 2015 Jul 1. J Immunol. 2015. PMID: 26136429 Free PMC article. - Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation.
Sander B, Campo E, Hsi ED. Sander B, et al. Virchows Arch. 2023 Jan;482(1):131-145. doi: 10.1007/s00428-022-03460-y. Epub 2022 Dec 1. Virchows Arch. 2023. PMID: 36454275 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources